Cargando…

Evaluation of pregnancy outcomes from the Tysabri® (natalizumab) pregnancy exposure registry: a global, observational, follow-up study

BACKGROUND: Patients with multiple sclerosis (MS) or Crohn’s disease (CD) being treated with natalizumab (Tysabri®, Biogen) who are planning to become pregnant or discover they are pregnant after exposure to natalizumab are currently advised to balance the potential benefits and potential risks of e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Friend, Susan, Richman, Sandra, Bloomgren, Gary, Cristiano, Lynda M., Wenten, Madé
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4995778/ https://www.ncbi.nlm.nih.gov/pubmed/27552976 http://dx.doi.org/10.1186/s12883-016-0674-4

Ejemplares similares

Outcome and survival of asymptomatic PML in natalizumab-treated MS patients
por: Dong-Si, Tuan, et al.
Publicado: (2014)

Predictors of survival and functional outcomes in natalizumab-associated progressive multifocal leukoencephalopathy
por: Dong-Si, Tuan, et al.
Publicado: (2015)

Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data
por: Bloomgren, Gary, et al.
Publicado: (2012)

Long-term safety and effectiveness of natalizumab treatment in clinical practice: 10 years of real-world data from the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2020)

Exposure to natalizumab during pregnancy and lactation is safe – No
por: Airas, Laura
Publicado: (2020)

M125. DISEASE PREVALENCE, COMORBID CONDITIONS, AND MEDICATION UTILIZATION AMONG PATIENTS WITH SCHIZOPHRENIA IN THE UNITED STATES
por: Roy, Brittany, et al.
Publicado: (2020)

Correlation of disability with quality of life in patients with multiple sclerosis treated with natalizumab: primary results and post hoc analysis of the TYSabri ImPROvement study (PROTYS)
por: Achtnichts, Lutz, et al.
Publicado: (2023)

Bacterial meningitis in a patient with multiple sclerosis receiving Tysabri
por: Moghadasi, Abdorreza Naser, et al.
Publicado: (2016)

No evidence for loss of natalizumab effectiveness with every-6-week dosing: a propensity score–matched comparison with every-4-week dosing in patients enrolled in the Tysabri Observational Program (TOP)
por: Butzkueven, Helmut, et al.
Publicado: (2021)

Anti–JC virus antibody levels in serum or plasma further define risk of natalizumab-associated progressive multifocal leukoencephalopathy
por: Plavina, Tatiana, et al.
Publicado: (2014)

Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP)
por: Wiendl, Heinz, et al.
Publicado: (2016)

Erythropoietin therapy in a case of neonatal anemia after exposure to natalizumab throughout pregnancy
por: Godano, Elisabetta, et al.
Publicado: (2021)

Exposure to quadrivalent influenza vaccine during pregnancy: Results from a global pregnancy registry
por: Ledlie, Shaleesa, et al.
Publicado: (2021)

Multiple Sclerosis Disease Activity and Disability Following Discontinuation of Natalizumab for Pregnancy
por: Hellwig, Kerstin, et al.
Publicado: (2022)

Disease activity following pregnancy-related discontinuation of natalizumab in MS
por: Kleerekooper, Iris, et al.
Publicado: (2017)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis
por: Toorop, Alyssa A, et al.
Publicado: (2021)

Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry
por: Guger, Michael, et al.
Publicado: (2020)

Disease activity in pregnancy and postpartum in women with MS who suspended rituximab and natalizumab
por: Razaz, Neda, et al.
Publicado: (2020)

Natalizumab in the pediatric MS population: results of the Italian registry
por: Ghezzi, Angelo, et al.
Publicado: (2015)

Pregnancy Exposure Registries for Assessing Antimalarial Drug Safety in Pregnancy in Malaria-Endemic Countries
por: Dellicour, Stephanie, et al.
Publicado: (2008)

Evaluation of Opioid Overdose Reports in Patients Treated with Extended-Release Naltrexone: Postmarketing Data from 2006 to 2018
por: Jain, Priya, et al.
Publicado: (2020)

Natalizumab concentrations during pregnancy in three patients with multiple sclerosis: A clinical commentary
por: Dobson, Ruth, et al.
Publicado: (2022)

Seasonal influenza vaccine exposure in pregnancy: 5-year results from a pregnancy registry
por: Nwoji, Ugo
Publicado: (2021)

Cohort profile: the Western Cape Pregnancy Exposure Registry (WCPER)
por: Kalk, Emma, et al.
Publicado: (2022)

Pregnancy outcomes after early fetal exposure to injectable first‐line treatments, dimethyl fumarate, or natalizumab in Danish women with multiple sclerosis
por: Andersen, Johanna Balslev, et al.
Publicado: (2022)

Birth outcomes following antiretroviral exposure during pregnancy: Initial results from a pregnancy exposure registry in South Africa
por: Mehta, Ushma C., et al.
Publicado: (2019)

Drug and Neurofilament Levels in Serum and Breastmilk of Women With Multiple Sclerosis Exposed to Natalizumab During Pregnancy and Lactation
por: Proschmann, Undine, et al.
Publicado: (2021)

Timing and severity of COVID-19 during pregnancy and risk of preterm birth in the International Registry of Coronavirus Exposure in Pregnancy
por: Smith, Louisa H., et al.
Publicado: (2022)

Research: Treatment: Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study
por: Wenten, M, et al.
Publicado: (2012)

Protocol for a drugs exposure pregnancy registry for implementation in resource-limited settings
por: Mehta, Ushma, et al.
Publicado: (2012)

Turnover intention in new graduate nurses: a multivariate analysis
por: Beecroft, Pauline C, et al.
Publicado: (2008)

The Global Network Maternal Newborn Health Registry: a multi-national, community-based registry of pregnancy outcomes
por: Bose, Carl L, et al.
Publicado: (2015)

The Global Network Maternal Newborn Health Registry: a multi-country, community-based registry of pregnancy outcomes
por: McClure, Elizabeth M., et al.
Publicado: (2020)

Belimumab use during pregnancy: Interim results of the belimumab pregnancy registry
por: Juliao, Patricia, et al.
Publicado: (2022)

An international registry for emergent pathogens and pregnancy
por: Panchaud, Alice, et al.
Publicado: (2020)

Natalizumab-induced pneumonitis
por: Kaninia, Stefania, et al.
Publicado: (2021)

Natalizumab-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: Findings from an Italian Independent Registry
por: Prosperini, Luca, et al.
Publicado: (2016)

Disease Evolution in Women With Highly Active MS Who Suspended Natalizumab During Pregnancy vs Rituximab/Ocrelizumab Before Conception
por: Demortiere, Sarah, et al.
Publicado: (2023)

No Association Was Found Between Mild Iodine Deficiency During Pregnancy and Pregnancy Outcomes: a Follow-up Study Based on a Birth Registry
por: Cui, Xueying, et al.
Publicado: (2022)

Social determinants of health associated with COVID-19 severity during pregnancy: a multinational cohort study (in the International Registry of Coronavirus Exposure in Pregnancy)
por: Mack, Jasmine A, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_gb0oa42bkis1elbhmk6nve1v46